345 related articles for article (PubMed ID: 23537723)
1. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
Schulte S
Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
[TBL] [Abstract][Full Text] [Related]
2. Pioneering designs for recombinant coagulation factors.
Schulte S
Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
[TBL] [Abstract][Full Text] [Related]
3. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Santagostino E
Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
[TBL] [Abstract][Full Text] [Related]
4. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
5. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
Metzner HJ; Pipe SW; Weimer T; Schulte S
Thromb Haemost; 2013 Nov; 110(5):931-9. PubMed ID: 24178510
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B.
Martinowitz U; Lubetsky A
Thromb Res; 2013 Mar; 131 Suppl 2():S11-4. PubMed ID: 23537721
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
[TBL] [Abstract][Full Text] [Related]
8. Bringing new therapy options to the hemophilia community.
Bensen-Kennedy D
Thromb Res; 2013 Mar; 131 Suppl 2():S15-8. PubMed ID: 23537722
[TBL] [Abstract][Full Text] [Related]
9. Half-life extension through albumin fusion technologies.
Schulte S
Thromb Res; 2009 Dec; 124 Suppl 2():S6-8. PubMed ID: 20109653
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
Zollner S; Schuermann D; Raquet E; Mueller-Cohrs J; Weimer T; Pragst I; Dickneite G; Schulte S
J Thromb Haemost; 2014 Feb; 12(2):220-8. PubMed ID: 24641308
[TBL] [Abstract][Full Text] [Related]
11. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
Santagostino E
Thromb Res; 2016 May; 141 Suppl 3():S5-8. PubMed ID: 27288064
[TBL] [Abstract][Full Text] [Related]
12. Half-life extension technologies for haemostatic agents.
Mannucci PM
Thromb Haemost; 2015 Jan; 113(1):165-76. PubMed ID: 25274414
[TBL] [Abstract][Full Text] [Related]
13. Challenges for new haemophilia products from a manufacturer's perspective.
Schulte S
Thromb Res; 2014 Nov; 134 Suppl 1():S72-6. PubMed ID: 24360931
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats.
Herzog E; Harris S; Henson C; McEwen A; Schenk S; Nolte MW; Pragst I; Dickneite G; Schulte S; Zollner S
Thromb Res; 2014 May; 133(5):900-7. PubMed ID: 24680550
[TBL] [Abstract][Full Text] [Related]
15. A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.
Buyue Y; Liu T; Kulman JD; Toby GG; Kamphaus GD; Patarroyo-White S; Lu Q; Reidy TJ; Mei B; Jiang H; Pierce GF; Sommer JM; Peters RT
PLoS One; 2014; 9(11):e113600. PubMed ID: 25415306
[TBL] [Abstract][Full Text] [Related]
16. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.
Shapiro A
Expert Opin Biol Ther; 2013 Sep; 13(9):1287-97. PubMed ID: 23930915
[TBL] [Abstract][Full Text] [Related]
17. Increased potency of recombinant VWF D'D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII.
Chia J; Pestel S; Glauser I; Emmrich K; Hardy MP; Mischnik M; Raquet E; Tomasetig V; Claar P; Zalewski A; Bass GT; Turnbull V; Chen CG; Wilson MJ; Panousis C; Weimer T; Andrews A; Verhagen AM; Dower SK
J Thromb Haemost; 2021 Nov; 19(11):2710-2725. PubMed ID: 34333849
[TBL] [Abstract][Full Text] [Related]
18. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
[TBL] [Abstract][Full Text] [Related]
19. Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journey.
Négrier C
Thromb Res; 2016 May; 141 Suppl 3():S9-S12. PubMed ID: 27288065
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study.
Kenet G; Chambost H; Male C; Halimeh S; Lambert T; Li Y; Seifert W; Santagostino E
Thromb Haemost; 2020 Apr; 120(4):599-606. PubMed ID: 32185782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
